FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, in particular to a new antibody and a fragment of this antibody, which specifically bind to TIGIT, as well as to a composition including this antibody or its fragment. In addition, the present invention relates to nucleic acid encoding this antibody or its fragment, a host cell containing this nucleic acid, and their use. In addition, the present invention relates to therapeutic or diagnostic use of this antibody or its fragment.
EFFECT: obtaining an antibody to TIGIT.
21 cl, 9 dwg, 16 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ENGINEERED pH-DEPENDENT ANTI-CD3 ANTIBODIES, AS WELL AS METHODS FOR PRODUCTION AND USE THEREOF | 2020 |
|
RU2832079C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
